Back to results
US 2019/0314301 A1Published application
Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes
AssigneeAtrogi AB
InventorsBenjamin PELCMAN, Tore BENGTSSON
Life of this patent
Estimating the term…
Abstract
There is herein provided pharmaceutical formulations and kits-of-parts comprising a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a β3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof. This combination of active agents finds particular utility in the treatment of type 2 diabetes.
Claims17
A pharmaceutical formulation comprising:
- (a) a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof;
- and
- (b) a β3-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable excipient.
14-15. (canceled)
18-21. (canceled)
Dependencies are inferred from the claim text.